Chong, Elizabeth - Resultados de la búsqueda - Depósito Digital de Documentos de la UAB

Buscar colecciones:

Ordenar por:	Mostrar resultados:	Formato de visualización:

Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros

Artículos	Encontrados 2 registros

9 p, 442.2 KB

B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy / Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ; Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ; Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ; Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ; Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ; Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ; Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ; Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - DOI (Digital Object Identifier)

10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073

Registro completo -

16 p, 1.3 MB

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma / Mar, Nataliya (University of California Irvine) ; Zakharia, Yousef (University of Iowa Hospitals and Clinics) ; Falcon, Alejandro (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Morales-Barrera, Rafael (Vall d'Hebron Institut d'Oncologia) ; Mellado, Begoña (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Duran, Ignacio (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Oh, Do-Youn (Seoul National University Hospital) ; Williamson, Stephen K. (University of Kansas Hospital Cancer Center) ; Gajate, Pablo (Hospital Universitario Ramón y Cajal (Madrid)) ; Arkenau, Hendrik-Tobias (University College London Cancer Institute) ; Jones, Robert J. (BUniversity of Glasgow) ; Teo, Min Yuen (Memorial Sloan Kettering Cancer Center (Estats Units d'Amèrica)) ; Turan, Tolga (Pharmacyclics (Estats Units d'Amèrica)) ; McLaughlin, Robert T. (Pharmacyclics (Estats Units d'Amèrica)) ; Peltier, Hillary M. (Pharmacyclics (Estats Units d'Amèrica)) ; Chong, Elizabeth (Pharmacyclics (Estats Units d'Amèrica)) ; Atluri, Harisha (Pharmacyclics (Estats Units d'Amèrica)) ; Dean, James P. (Pharmacyclics (Estats Units d'Amèrica)) ; Castellano, Daniel (Hospital Universitario 12 de Octubre (Madrid)) ; Universitat Autònoma de Barcelona
Urothelial carcinoma (UC) is a common type of bladder cancer. Patients with UC that has not improved after previous treatment or has spread to other parts of the body need new treatment options. Ibrutinib is a drug approved for the treatment of blood cancers and chronic graft-versus-host disease. [...]
2023 - DOI (Digital Object Identifier)

10.3390/cancers15112978
Cancers, Vol. 15 (may 2023)

Registro completo -

Vea también: autores con nombres similares

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.